Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Tetanus × sargramostim × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 7 Lymphoma, Follicular 6 Leukemia 6 Prostatic Neoplasms 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Sarcoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Ovarian Neoplasms 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Mantle-Cell 3 Lymphoma, Large-Cell, Immunoblastic 3 Lymphoma, Large B-Cell, Diffuse 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Burkitt Lymphoma 3 Astrocytoma 3 Neoplasms, Plasma Cell 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Lymphoma, B-Cell, Marginal Zone 2 Leukemia, Myeloid, Chronic-Phase 2 Glioblastoma 2 Central Nervous System Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Wilms Tumor 1 Urinary Bladder Neoplasms 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Tetanus 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1

Interventions

sargramostim 1 Temozolomide 1 Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03927222 2024-04-08

I-ATTAC

Duke University

Phase 2 Terminated

6 enrolled 7 charts

Glioblastoma, Tetanus

Data powered by HemOnc (CC BY 4.0) Colophon ⚡